HBM Holdings Valuation Multiples

HBM Holdings Overview

About HBM Holdings

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

Founded

2016

HQ

Employees

177

Website

harbourbiomed.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $179M

EBITDA: $97M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

HBM Holdings Financials

HBM Holdings reported last 12-month revenue of $179M and EBITDA of $97M.

In the same LTM period, HBM Holdings generated $170M in gross profit, $97M in EBITDA, and $94M in net income.

HBM Holdings P&L

In the most recent fiscal year, HBM Holdings reported revenue of $38M and EBITDA of $10M.

HBM Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX

HBM Holdings Stock Performance

HBM Holdings has current market cap of $2B, and enterprise value of $1B.

HBM Holdings' stock price is $1.91.

HBM Holdings Valuation Multiples

HBM Holdings trades at 7.5x EV/Revenue multiple, and 13.8x EV/EBITDA.

HBM Holdings Financial Valuation Multiples

As of April 18, 2026, HBM Holdings has market cap of $2B and EV of $1B.

Equity research analysts estimate HBM Holdings' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

HBM Holdings has a P/E ratio of 17.0x.

HBM Holdings Margins & Growth Rates

HBM Holdings' revenue in the last 12 month grew by 29%.

HBM Holdings' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

HBM Holdings' rule of 40 is 87% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

HBM Holdings' rule of X is 155% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

HBM Holdings Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

HBM Holdings M&A Activity

HBM Holdings acquired XXX companies to date.

Last acquisition by HBM Holdings was on XXXXXXXX, XXXXX. HBM Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

HBM Holdings Investment Activity

HBM Holdings invested in XXX companies to date.

HBM Holdings made its latest investment on XXXXXXXX, XXXXX. HBM Holdings invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).